Henagliflozin
- Generic Name
- Henagliflozin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H24ClFO7
- CAS Number
- 1623804-44-3
- Unique Ingredient Identifier
- 21P2M98388
- Background
Henagliflozin has been used in trials studying the treatment of Type 2 Diabetes.
- Associated Conditions
- -
- Associated Therapies
- -
Henagliflozin in Relieving Type 2 Diabetes With Non-alcoholic Fatty Liver Disease
Phase 4
Not yet recruiting
- Conditions
- Type 2 DiabetesNon-Alcoholic Fatty Liver Disease
- Interventions
- Other: Background medicationDrug: Henagliflozin
- First Posted Date
- 2024-01-23
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Sir Run Run Shaw Hospital
- Target Recruit Count
- 156
- Registration Number
- NCT06218342
Efficacy of Henagliflozin for Weight Loss in Obesity Without Diabetes
Phase 4
Not yet recruiting
- Conditions
- ObeseWeight LossPre-diabetes
- Interventions
- Drug: PlaceboDrug: Henagliflozin
- First Posted Date
- 2024-01-22
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- The First People's Hospital of Changzhou
- Target Recruit Count
- 300
- Registration Number
- NCT06216340
Henagliflozin Reducing Infarct Size After Priamry PCI in Patients With ST Segment Elevation Myocardial Infarction
- First Posted Date
- 2024-01-03
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- Qian geng
- Target Recruit Count
- 240
- Registration Number
- NCT06187727
- Locations
- 🇨🇳
Chinese PLA general hospital, Beijing, Beijing, China
Effects of Henagliflozin on the Brain Function in T2DM Patients With Mild Cognitive Impairment: a Randomized, Parallel Controlled Clinical Trial
Not Applicable
Recruiting
- Conditions
- Type 2 Diabetes MellitusMild Cognitive Impairment
- Interventions
- First Posted Date
- 2023-10-17
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Target Recruit Count
- 60
- Registration Number
- NCT06085703
- Locations
- 🇨🇳
Division of Endocrinology, the Affiliated Drum Tower Hospital of Nanjing University, Nanjing, Jiangsu, China
The Effect of Henagliflozin and Metformin on Myocardial Tissue-level Characteristics
Not Applicable
Not yet recruiting
- Conditions
- Sodium-glucose Co-transporter-2 InhibitorMagnetic Resonance ImagingObesityType 2 DiabetesMyocardial Fibrosis
- Interventions
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 64
- Registration Number
- NCT06059287
Henagliflozin Delays the Progress of Diabetic Nephropathy Via Regulates Gut-Renal Axis
Not Applicable
Not yet recruiting
- Conditions
- Diabetic Nephropathies
- Interventions
- Drug: PlaceboDrug: Henagliflozin
- First Posted Date
- 2023-09-11
- Last Posted Date
- 2023-09-11
- Lead Sponsor
- Qianfoshan Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT06031389
Combination of Henagliflozin and Continuous Subcutaneous Insulin Infusion in T2DM
Phase 4
Recruiting
- Conditions
- Type2diabetes
- Interventions
- Device: Continuous Subcutaneous Insulin InfusionDrug: Henagliflozin
- First Posted Date
- 2023-01-10
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- First Affiliated Hospital of Guangxi Medical University
- Target Recruit Count
- 200
- Registration Number
- NCT05677334
- Locations
- 🇨🇳
First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath